Login / Signup

Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Qin-Yi SuJing LuoXin-Miao WangJing-Kai DiYi-Xin CaoSheng-Xiao Zhang
Published in: Immunity, inflammation and disease (2024)
LD-IL-2 was promising and well-tolerated in treating SLE, which could promote Treg's proliferation and functional recovery. Injecting 0.5 million IU of IL-2 daily can better induce the differentiation of Treg cells and maintain immune homeostasis than injecting 1 million IU every other day.
Keyphrases
  • low dose
  • induced apoptosis
  • systemic lupus erythematosus
  • peripheral blood
  • signaling pathway
  • cell cycle arrest
  • physical activity
  • high dose
  • rheumatoid arthritis
  • disease activity
  • pi k akt